New hope for ALK lung cancer: targeted drug brigatinib tested in phase 2 trial

NCT ID NCT04318938

First seen Jan 11, 2026 · Last updated May 02, 2026 · Updated 19 times

Summary

This study tests the drug brigatinib in 118 adults with advanced ALK-positive non-small cell lung cancer. The goal is to see how long the drug can keep the cancer from growing. Participants take brigatinib as their first treatment, and researchers track tumor progression and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Charité Berlin

    Berlin, Germany

  • Evangelisches Krankenhaus Hamm

    Hamm, Germany

  • HELIOS Klinikum Emil von Behring

    Berlin, 14165, Germany

  • KRH Klinikum Siloah Hannover

    Hanover, 30459, Germany

  • Klinik Schillerhöhe

    Stuttgart, Germany

  • Klinik der LMU München - Innenstadt

    München, Germany

  • Klinikum Esslingen

    Esslingen am Neckar, 73730, Germany

  • Klinikum Nürnberg

    Nuremberg, 90419, Germany

  • Krankenhaus Nordwest Frankfurt

    Frankfurt am Main, 60488, Germany

  • Lungenklinik Hemer

    Hemer, Germany

  • Lungenklinik Köln - Merheim

    Cologne, 51109, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Niels-Stensen-Kliniken Georgsmarienhütte

    Georgsmarienhütte, 49124, Germany

  • Pius Hospital Oldenburg

    Oldenburg, 26121, Germany

  • Studiengesellschaft Hämato-Onkologie Hamburg

    Hamburg, 20251, Germany

  • Thoraxklinik am Universitätsklinikum Heidelberg

    Heidelberg, 69126, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Universitätsklinikum Gießen

    Giessen, Germany

  • Universitätsklinikum Jena

    Jena, 07740, Germany

  • Universitätsklinikum Leipzig

    Leipzig, 04103, Germany

  • Universitätsklinikum Münster

    Münster, Germany

  • Universitätsklinikum Regensburg

    Regensburg, 93053, Germany

  • Universitätsklinikum Ulm

    Ulm, 89081, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Germany

  • Universitätsmedizin Essen

    Essen, 45147, Germany

  • Universitätsmedizin Mainz

    Mainz, 55131, Germany

Conditions

Explore the condition pages connected to this study.